Skip to content

Study of Paliperidone ER in Adolescents and Young Adults With Autism

A Prospective, Open-Label Study of Paliperidone ER in Adolescents and Young Adults With Autism

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00549562
Enrollment
25
Registered
2007-10-26
Start date
2007-11-30
Completion date
2010-09-30
Last updated
2017-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism

Keywords

Autistic Disorder

Brief summary

This 8-week, prospective open-label study will investigate the effectiveness and tolerability of paliperidone ER in adolescents and young adults with autism. Hypothesis:Paliperidone Er will be well tolerated and efficacious for reducing aggression, self-injury, and irritability in adolescents and young adults.

Interventions

DRUGPaliperidone ER

Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.

Sponsors

Ortho-McNeil Janssen Scientific Affairs, LLC
CollaboratorINDUSTRY
Indiana University School of Medicine
Lead SponsorOTHER

Study design

Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* Males and females between ages of 12 and 21 years * Tanner Sage III or IV (post-pubertal) * Diagnostic and Statistical Manual Fourth Edition Text-Revised (DSM-IV-TR) diagnosis of autism * Outpatient * Ability to swallow pills * Antipsychotic medication-free for at least 2 weeks * Score of 4 or more on the Clinical Global Impressions Severity Scale * Score of 18 or higher on the Aberrant Behavior Checklist Irritability Scale * Mental age of 18 months or greater based on testing * Subjects must be in good physical health

Exclusion criteria

* Asperger's Disorder, Pervasive Developmental Disorder Not Otherwise Specified (PDD NOS), Rett's Disorder, childhood disintegrative disorder, schizophrenia, bipolar disorder, Fragile X Syndrome, Tuberous Sclerosis * A significant medical condition * An active seizure disorder * Females who are pregnant * Evidence of a prior adequate trial of paliperidone ER * History of neuroleptic malignant syndrome * Hypersensitivity to paliperidone ER

Design outcomes

Primary

MeasureTime frameDescription
The Clinical Global Impression-Improvement(CGI-I)Week 8The CGI Global Improvement (CGI-I) is a clinician-rate scale designed to take into account all factors to arrive at an assessment of severity and response to treatment, including parent report, parent-rated measures, teacher-rated measures, and clinician-rated measures. The CGI-I is rated from 1 to 7 (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) at a single time-point.
The Aberrant Behavior ChecklistWeek 8The Aberrant Behavior Checklist (ABC) is a 58-item measure of maladaptive behaviors and is used as a measure of drug effects. Each item is rated from 0 (not at all to 3 (severe). The ABC has 5 subscales:Irritability (15 items) ranging from 0 (not at all) to 45 (severe), Hyperactivity (16 items) ranging from 0 (not at all) to 48 (severe), Social Withdrawal (16 items) ranging from 0 (not at all) to 48 (severe), Stereotypy (7 items) ranging from 0 (not at all) to 21 (severe) and Inappropriate Speech (4 items) ranging from 0 (not at all) to 12 (severe).

Secondary

MeasureTime frameDescription
The Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental DisordersWeek 8The Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders (CY-BOCS-PDD) is semi-structured clinician rating scale designed to rate the current severity of repetitive behavior in children and adolescents with PDD. The scale consists of 5 items: Time Spent, Interference, Distress, Resistance and Control. Each item is scored from 0 (None) to 4 (Extreme). The scale yields a Total Score from 0 (least symptomatic) to 20 (most symptomatic). Higher scores indicate greater severity of repetitive behavior.
The Social Responsiveness ScaleWeek 8The Social Responsiveness Scale (SRS) is a 65-item parent completed scale that assesses social awareness, social cognition, social communication, social motivation and autistic mannerisms. Each item is scored from 1 (not true) to 3 (almost always true). Interpretation in this study is based on a total score that is proportional to the level of impairment in reciprocal social behavior. Scores within 0-53 are within normal limits. Scores within 54-86 indicate mild to moderate impairment. Scores above 87 indicate severe impairment.
The Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior DomainWeek 8The VABS Maladaptive Behavior Domain measures undesirable behaviors that may interfere with an individual's adaptive functioning. The Maladaptive Domain consists two parts. Part I contains 27 minor maladaptive items and Part II contains 9 serious maladaptive behaviors. Each item is scored from 0 (never or seldom engages in the activity) to 2(usually or habitually engages in the activity). Part 1 yields a score of 0 to 54. Part II yields a score of 0 to 18. Both parts are combined to make a Total Score of 0 to 72. High scores of maladaptive behaviors reflect more negative behavior.

Countries

United States

Participant flow

Participants by arm

ArmCount
Paliperidone ER
8-Week Open-Label Paliperidone ER: starting dose is 3 mg per day, with the option to increase the dose by 3 mg/day on a weekly basis for 4 weeks to a maximum dose of 12 mg per day.
25
Total25

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event1
Overall StudyLack of Efficacy1

Baseline characteristics

CharacteristicPaliperidone ER
Age, Categorical
<=18 years
20 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
5 Participants
Age, Continuous15.36 Years
Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders16 units on a scale
STANDARD_DEVIATION 3
Clinical Global Impressions-Improvement (CGI-I)4.0 units on a scale
STANDARD_DEVIATION 0
Region of Enrollment
United States
25 participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
21 Participants
The Aberrant Behavior Checklist
ABC-Hyperactivity
34.7 units on a scale
STANDARD_DEVIATION 8.9
The Aberrant Behavior Checklist
ABC-Inappropriate Speech
7.5 units on a scale
STANDARD_DEVIATION 4.4
The Aberrant Behavior Checklist
ABC-Irritability
30.3 units on a scale
STANDARD_DEVIATION 6.5
The Aberrant Behavior Checklist
ABC-Social Withdrawal
17.2 units on a scale
STANDARD_DEVIATION 12.5
The Aberrant Behavior Checklist
ABC-Stereotypy
12.5 units on a scale
STANDARD_DEVIATION 6.7
The Social Responsiveness Scale122.6 units on a scale
STANDARD_DEVIATION 18.4
The Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior Domain
VABS Maladaptive Behavior Subscale Part I
28.9 units on a scale
STANDARD_DEVIATION 6.3
The Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior Domain
VABS Maladaptive Behavior Subscale Part II
8.8 units on a scale
STANDARD_DEVIATION 6.4
The Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior Domain
VABS Maladaptive Behavior Subscale Total
37.4 units on a scale
STANDARD_DEVIATION 8.2

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 25
other
Total, other adverse events
21 / 25
serious
Total, serious adverse events
0 / 25

Outcome results

Primary

The Aberrant Behavior Checklist

The Aberrant Behavior Checklist (ABC) is a 58-item measure of maladaptive behaviors and is used as a measure of drug effects. Each item is rated from 0 (not at all to 3 (severe). The ABC has 5 subscales:Irritability (15 items) ranging from 0 (not at all) to 45 (severe), Hyperactivity (16 items) ranging from 0 (not at all) to 48 (severe), Social Withdrawal (16 items) ranging from 0 (not at all) to 48 (severe), Stereotypy (7 items) ranging from 0 (not at all) to 21 (severe) and Inappropriate Speech (4 items) ranging from 0 (not at all) to 12 (severe).

Time frame: Week 8

ArmMeasureGroupValue (MEAN)Dispersion
Paliperidone ERThe Aberrant Behavior ChecklistABC-Irritability12.6 units on a scaleStandard Deviation 9.1
Paliperidone ERThe Aberrant Behavior ChecklistABC-Hyperactivity17.4 units on a scaleStandard Deviation 11.5
Paliperidone ERThe Aberrant Behavior ChecklistABC-Social Withdrawal7.6 units on a scaleStandard Deviation 8.8
Paliperidone ERThe Aberrant Behavior ChecklistABC-Stereotypy6.4 units on a scaleStandard Deviation 5.1
Paliperidone ERThe Aberrant Behavior ChecklistABC-Inappropriate Speech3.4 units on a scaleStandard Deviation 3.8
Primary

The Clinical Global Impression-Improvement(CGI-I)

The CGI Global Improvement (CGI-I) is a clinician-rate scale designed to take into account all factors to arrive at an assessment of severity and response to treatment, including parent report, parent-rated measures, teacher-rated measures, and clinician-rated measures. The CGI-I is rated from 1 to 7 (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) at a single time-point.

Time frame: Week 8

ArmMeasureValue (MEAN)Dispersion
Paliperidone ERThe Clinical Global Impression-Improvement(CGI-I)1.8 units on a scaleStandard Deviation 1.3
Secondary

The Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders

The Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders (CY-BOCS-PDD) is semi-structured clinician rating scale designed to rate the current severity of repetitive behavior in children and adolescents with PDD. The scale consists of 5 items: Time Spent, Interference, Distress, Resistance and Control. Each item is scored from 0 (None) to 4 (Extreme). The scale yields a Total Score from 0 (least symptomatic) to 20 (most symptomatic). Higher scores indicate greater severity of repetitive behavior.

Time frame: Week 8

ArmMeasureValue (MEAN)Dispersion
Paliperidone ERThe Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders11.9 units on a scaleStandard Deviation 4
Secondary

The Social Responsiveness Scale

The Social Responsiveness Scale (SRS) is a 65-item parent completed scale that assesses social awareness, social cognition, social communication, social motivation and autistic mannerisms. Each item is scored from 1 (not true) to 3 (almost always true). Interpretation in this study is based on a total score that is proportional to the level of impairment in reciprocal social behavior. Scores within 0-53 are within normal limits. Scores within 54-86 indicate mild to moderate impairment. Scores above 87 indicate severe impairment.

Time frame: Week 8

ArmMeasureValue (MEAN)Dispersion
Paliperidone ERThe Social Responsiveness Scale100.9 units on a scaleStandard Deviation 20.4
Secondary

The Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior Domain

The VABS Maladaptive Behavior Domain measures undesirable behaviors that may interfere with an individual's adaptive functioning. The Maladaptive Domain consists two parts. Part I contains 27 minor maladaptive items and Part II contains 9 serious maladaptive behaviors. Each item is scored from 0 (never or seldom engages in the activity) to 2(usually or habitually engages in the activity). Part 1 yields a score of 0 to 54. Part II yields a score of 0 to 18. Both parts are combined to make a Total Score of 0 to 72. High scores of maladaptive behaviors reflect more negative behavior.

Time frame: Week 8

ArmMeasureGroupValue (MEAN)Dispersion
Paliperidone ERThe Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior DomainVABS Maladaptive Behavior Subjscale Part II6.4 units on a scaleStandard Deviation 3.4
Paliperidone ERThe Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior DomainVABS Maladaptive Behavior Subscale Total25.1 units on a scaleStandard Deviation 8.8
Paliperidone ERThe Vineland Adaptive Behavior Scales (VABS) - Maladaptive Behavior DomainVABS Maladaptive Behavior Subscale-Part I19.0 units on a scaleStandard Deviation 6.9

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026